Document Detail

Ocular Surface Changes in Glaucomatous Patients Treated With and Without Preservatives Beta-Blockers.
MedLine Citation:
PMID:  24787056     Owner:  NLM     Status:  Publisher    
Abstract Purpose: To determine whether there were ocular surface changes in glaucomatous patients treated with preservatives beta-blockers who switched to preservative-free beta-blockers. Methods: This was a prospective, longitudinal, open-labeled study. One hundred thirty-two patients with primary open angle glaucoma treated with a preserved beta-blocker were enrolled. All the patients underwent perimetric and gonioscopic examination, complete ophthalmologic examination, intraocular pressure (IOP) measurements, evaluation of ocular surface, Schirmer's test, blood pressure and heart rate at baseline and 1-3 months after changing the medical treatment to a preservative-free timolol 0.1% (Timogel 0.1; Thea). At baseline, after 1 month and at the end of the study (3 months), all patients underwent a questionnaire on the visual quality and symptoms and on the quality of life (QoL). Data were analyzed by t-test when the distribution of the data was normal, by Mann-Whitney when the distribution was not normal. Results: No significant difference was found for IOP before switching from preserved beta-blockers to preservative-free ones. No significant difference was found in blood pressure and heart rate. However, a statistically significant difference was found for abnormal fluorescein staining of the cornea and conjunctiva, eyelid erythema, conjunctival hyperemia, and follicular hyperplasia. A significant difference was found for break-up time (from 9.38±4.7 s at baseline to 10.64±4.7 s after 3 months) and Schirmer's test (from 12.9±5.96 mm at baseline to 14.2±5.87 mm after 3 months). The questionnaire showed that the patient improved the dryness and foreign body sensation. Conclusion: In glaucomatous patients, preservative-free 0.1 timolol treatment improved their QoL. Similar dry eye signs or symptoms improved after 3 months of treatment reducing dryness, hyperemia, follicular hyperplasia, and foreign body sensation.
Michele Iester; Serena Telani; Paolo Frezzotti; Ilaria Motolese; Michele Figus; Paolo Fogagnolo; Andrea Perdicchi
Related Documents :
25076366 - Life quality assessment of patients after phacoemulsification or extracapsular cataract...
9136776 - Gastric emptying following pylorus-preserving whipple and duodenum-preserving pancreati...
15173796 - A simple way of avoiding post-ercp pancreatitis.
24427446 - Total hip and knee replacement in the mature athlete.
25397516 - Phase iiib, open-label single-arm trial of darunavir/cobicistat (drv/cobi): week 48 sub...
15807826 - Effect of mitomycin c on ciliary body and intraocular pressure with various application...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-4-30
Journal Detail:
Title:  Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics     Volume:  -     ISSN:  1557-7732     ISO Abbreviation:  J Ocul Pharmacol Ther     Publication Date:  2014 Apr 
Date Detail:
Created Date:  2014-5-2     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9511091     Medline TA:  J Ocul Pharmacol Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Expansion of the Litopenaeus vannamei and Penaeus monodon peptidomes using transcriptome shotgun ass...
Next Document:  Vitamin D insufficiency and schizophrenia risk: Evaluation of hyperprolinemia as a mediator of assoc...